Traws Pharma, Inc.

Traws Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for respiratory viral diseases and cancers. The company's lead infectious disease programs include tivoxavir marboxil, an oral cap-dependent endonuclease inhibitor evaluated for avian and seasonal influenza, and ratutrelvir, a main protease inhibitor investigated for COVID-19 treatment. Its oncology assets comprise narazaciclib, a multi-targeted kinase inhibitor targeting cyclin-dependent kinases for solid tumors and hematological cancers, and rigosertib, a polo-like kinase 1 inhibitor evaluated in rare skin cancers and RASopathy-related conditions. As a development-stage enterprise, Traws Pharma does not sell commercial products directly to consumers; its activities center on advancing investigational treatments through clinical trials and collaborating with biopharmaceutical partners and government agencies.

The company operates internationally, conducting and sponsoring clinical trials and research in the United States, Australia, the United Kingdom, Russia, and Greater China. Commercialization and development rights for its oncology pipeline involve partnerships across international regions, including licensing collaborations covering China. Traws Pharma is headquartered in the United States, where it interfaces with domestic regulatory bodies and government stakeholders.

Summary of the business section of Traws Pharma's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had 7 employees (4 of whom were full-time employees), in addition to various independent contractors working for us.”